Compare Quest Diagnostics Inc (DGX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Charles Schwab Corporation Common Stock — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 6.6× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| DGX | SCHW | |
|---|---|---|
Market Cap | $25.48B | $167.52B |
Volume | 941,866 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $247.45 | $113.65 |
52-Week Low | $173.49 | $85.35 |
Typical Hold Time | 56 Days | 85 Days |
Enterprise Value | $31.23B | $153.97B |
Dividend Yield | 1.49% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Charles Schwab (SCHW) trades at $96.87, up 1.35% with strong fundamentals including 37% net margin and consistent earnings beats. Technical indicators show bearish momentum near key support at $96, while fundamentals reveal robust revenue growth to $23.92B in 2025 and improving cash flow. The company demonstrates operational strength with client assets reaching $13.41T in August 2026 and strategic AI integration with Anthropic.
Outlook remains positive with 56.9% analyst buy ratings and $120.33 consensus target, though near-term technical weakness and competitive pressures pose risks. Earnings momentum and market share gains in the growing e-brokerage sector support upside potential, while interest rate sensitivity and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
